Uncaria tomentosa for Reducing Side Effects Caused by Chemotherapy in CRC Patients: Clinical Trial
Table 4
Evaluation of lipid peroxidation, carbonylation of serum protein, DNA damage and antioxidant defenses of the CRC patients in adjuvant/palliative chemotherapy (FOLFOX4), without Uncaria tomentosa supply (C group) or receiving 300 mg/day of Uncaria tomentosa (UT group).
Parameters
Group
Chemotherapy cycles
0
1
2
3
4
5
6
TBARS nmol
UT
16.7
16.2
18.3
17.9
17.7
17.8
21.6
MDA/mL
(9.34)
(7.1)
(7.2)
(6.9)
(4.1)
(3.4)
(11.8)
C
22.5
18.8
17.8
19.4
21.2
22.4
22.9
(11.6)
(10.9)
(11.3)
(10.5)
(8.9)
(9.7)
(10.5)
Protein carbonyl
UT
0.63
0.56
0.61
0.61
0.68
0.67
0.6
nmol/mg protein
(0.2)
(0.2)
(0.17)
(0.18)
(0.26)
(0.2)
(0.2)
C
0.79
0.77
0.73
0.72
0.78
0.9
0.84
(0.37)
(0.4)
(0.39)
(0.36)
(0.37)
(0.43)
(0.37)
Comet assay
UT
29.04
26.78
Index damage
(34.18)
(31.99)
C
26.94
34.66
(49.3)
(46.63)
Catalase
UT
7.85
8.2
7.65
9.12
8.97
9.33
10.39
pmol/mg protein
(3.3)
(3.0)
(2.81)
(4.75)
(4.71)
(3.27)
(4.08)
C
9.05
8.29
8.51
8.06
9.07
8.31
9.38
(4.9)
(2.7)
(4.05)
(3.51)
(3.71)
(3.07)
(3.78)
SOD
UT
1.82
1.85
1.95
2.19
1.95
2.29*
2.41*
U/mg protein
(0.5)
(0.44)
(0.44)
(0.43)
(0.43)
(0.44)
(0.56)
C
1.91
1.91
2.1
2.15
2.09
2.12
2.13
(0.8)
(0.76)
(0.71)
(0.78)
(0.7)
(0.81)
(0.72)
Data expressed in mean (SD). TBARS, thiobarbituric acid-reactive substances; SOD, superoxide dismutase; UT group: patients treated with FOLFOX4 + Uncaria tomentosa 300 mg/daily (); C group: CRC patients received FOLFOX4 (). * in relation to the day 0.
